ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2435

Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics

Marie Binvignat1, Brenda Miao2, Camilla Wibrand3, Monica Yang4, Dmitry Rychkov5, Emily Flynn4, Umair Khan4, Joanne Nititham6, Alex Carvidi4, Melissa Krueger4, Erene Niemi4, Yang Sun4, Gabriella Fragiadakis4, David Klatzmann1, Jeremie SELLAM7, Encarnita Mariotti-Ferrandiz1, Andrew Gross4, Chun Jimmie Ye4, Atul Butte4, Lindsey Criswell6, Mary Nakamura8 and Marina Sirota5, 1Sorbonne Université, Paris, France, 2University of California San Francisco, Fremont, CA, 3Aarhus University, Aarhus, Denmark, and University of California San Francisco, San Francisco, CA, 4University of California San Francisco, San Francisco, CA, 5Bakar Computational Health Sciences Institute, University of California San Francisco, San Francisco, CA, 6NIH/NHGRI, Bethesda, MD, 7Sorbonne Université APHP, Paris, France, 8UCSF/SFVAHCS, San Francisco, CA

Meeting: ACR Convergence 2023

Keywords: Bioinformatics, Biomarkers, Disease Activity, immunology, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: RA – Etiology & Pathogenesis

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Single cell transcriptional profiling (scRNA-Seq) is valuable in identifying gene signatures and cell subpopulations associated with rheumatoid arthritis (RA). However prior studies have often overlooked important demographic confounders and not focused on non-remission and difficult to treat RA. The aim of this study is to identify peripheral blood mononuclear cells (PBMCs) of RA and disease-activity cell subsets and gene signatures in a diverse population of patients.

Methods: 10X Chromium single cell sequencing was performed on peripheral blood mononuclear cells (PBMC) from 18 early RA patients and 18 healthy controls matched on age, sex, race and ethnicity. Data were processed using standard CellRanger and Scanpy pipelines, with HarmonyPy for batch correction. Differential expression (DE) was computed using pseudobulk analysis and DESeq2. Pathway analysis was carried out with over-representation analysis (ORA). Mann-Whitney tests were used to assess differences in cell proportions between matched RA and control samples, as well as between RA patients with low disease activity or remission (DAS28-CRP< 3.2; n=9) versus moderate or high disease activity (DAS28 CRP≥3.2;n=7). Ligand-receptor interaction analysis was performed using Cellchatdb.

Results: The final dataset consisted of 22,159 genes across 125,698 cells. We identified 18 PBMC subsets, including 5 CD4+ T cell subsets, 3 CD8+ T cell subsets, 2 Natural Killer cell subsets, 3 B cell subsets, and 5 monocyte subsets (Figure 1). Within these subsets, IFIT CD4 T+ cells and IFITM3 monocytes were associated with Interferon-gamma response. 168 genes were DE between RA and matched controls (FDR≤0.05, foldchange >1.6). We identified up-regulation of pro-inflammatory genes associated with monocyte subsets and downregulation of inflammatory genes in gamma-delta T cells. Several genes associated with RA predisposition such as HLA-DRB5 and HLA-DQB1 were specifically downregulated in IFITM3 monocytes (Figure 2). Functional analysis and ORA highlighted significant enrichment of B cell activation and B cell receptor signaling pathways. Differences in cell subset proportions between patients with high and moderate activity, patients in low disease activity and remission, and healthy controls (n=18, Figure 3) were also observed. Non classical monocytes and T central memory were decreased in patients with high disease activity compared to control and high disease activity (p=0.022; p=0.034). We also identified a specific signature of 49 genes, including IFNG, TNF, KLRD, EGR1, CBX6, CXCR4, JUN, and TLE3, that was significantly associated with disease activity. Finally, cell communication analysis between patients with high disease activity and controls revealed upregulation of IFN-II, VEGF, VISTA, BTLA, and CD40 pathway signaling.

Conclusion: Here we describe a dataset of scRNA-Seq PBMCs from a diverse population of patients with RA and matched healthy controls. We identify differentially expressed genes and cell subsets linked to disease activity, providing insights into RA pathophysiology and potentially new therapeutic targets.

Supporting image 1

Figure 1 | A. Graphical Abstract. B. UMAP embeddings and subset annotations of single cell RNAseq dataset from patients with rheumatoid arthritis (n=18) and healthy controls (n=18) matched on age, sex, and ethnicity. CD, Cluster differentiation; DCs, Dendritics cells; IFIT, Interferon Induced proteins with Tetratricopeptide repeats; IFITM, interferon-induced transmembrane; Tem: T effector memory, TEMRA: Terminally differentiated effector memory. RA Rheumatoid ArthritisTem: T effector memory, TEMRA: Terminally differentiated effector memory. RA Rheumatoid Arthritis

Supporting image 2

Figure 2 | A. Single cell UMAP projection of patients with rheumatoid arthritis and matched controls. . B Differentially expressed genes between patients with RA and matched controls. C. Upsets pot of upregulated and downregulated genes. CD, Cluster differentiation; DCs, Dendritics cells; IFIT, Interferon Induced proteins with Tetratricopeptide repeats; IFITM, interferon-induced transmembrane; Tem: T effector memory, TEMRA: Terminally differentiated effector memory. RA Rheumatoid Arthritis

Supporting image 3

Figure 3 | A. Compositional, density and cell proportion analysis between control patients with low disease and high activity (Mann-Whitney – Wilcoxon p≤ 0.05). B. Genes expression heatmap between controls and RA with low and high disease activity and average expression across cell subtypes C. Communication pathway significantly up and downregulated in high disease activity and controls, overview of cell communication within the VISA and the CD99 pathway. CD, Cluster differentiation; DCs, Dendritics cells; IFIT, Interferon Induced proteins with Tetratricopeptide repeats; IFITM, interferon-induced transmembrane; Tem: T effector memory, TEMRA: Terminally differentiated effector memory. RA Rheumatoid Arthritis


Disclosures: M. Binvignat: None; B. Miao: None; C. Wibrand: AMBU, 11, GenMab, 11, Lundbeck, 11, NovoNordisk, 11; M. Yang: None; D. Rychkov: None; E. Flynn: None; U. Khan: None; J. Nititham: None; A. Carvidi: None; M. Krueger: None; E. Niemi: None; Y. Sun: None; G. Fragiadakis: None; D. Klatzmann: None; J. SELLAM: None; E. Mariotti-Ferrandiz: None; A. Gross: None; C. Ye: Chan Zuckerberg Initiative, 5, Genentech, 5, ImmunAI, 1, 8, Maze Therapeutics, 2, 8, Related Sciences, 1, 8, TReX Bio, 2; A. Butte: 10X Genomics Health, 2, Genentech, 1, Mango Tree, 2, Merck/MSD, 1, Novartis, 1, NuMedii, 2, 8, personalis, 2, 4, 8, Roche, 1, samsung, 2, Verinata (Illumina), 2; L. Criswell: None; M. Nakamura: None; M. Sirota: Exxagen, 1.

To cite this abstract in AMA style:

Binvignat M, Miao B, Wibrand C, Yang M, Rychkov D, Flynn E, Khan U, Nititham J, Carvidi A, Krueger M, Niemi E, Sun Y, Fragiadakis G, Klatzmann D, SELLAM J, Mariotti-Ferrandiz E, Gross A, Ye C, Butte A, Criswell L, Nakamura M, Sirota M. Deciphering Rheumatoid Arthritis Disease Activity-Associated Gene Signatures and Cell Subsets Through Single Cell Transcriptomics [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/deciphering-rheumatoid-arthritis-disease-activity-associated-gene-signatures-and-cell-subsets-through-single-cell-transcriptomics/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/deciphering-rheumatoid-arthritis-disease-activity-associated-gene-signatures-and-cell-subsets-through-single-cell-transcriptomics/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology